Impact of dexamethasone in severe COVID-19-induced acute kidney injury: a multicenter cohort study
| dc.rights.license | open | en_US |
| hal.structure.identifier | Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases | |
| dc.contributor.author | RUBIN, Sebastien | |
| dc.contributor.author | ORIEUX, Arthur | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | PREZELIN-REYDIT, Mathilde | |
| dc.contributor.author | GARRIC, Antoine | |
| dc.contributor.author | PICARD, Yoann | |
| dc.contributor.author | MELLATI, Nouchan | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | LE GALL, Lisa
IDREF: 222223472 | |
| dc.contributor.author | DEWITTE, Antoine | |
| hal.structure.identifier | Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] [CRCTB] | |
| dc.contributor.author | PREVEL, Renaud | |
| hal.structure.identifier | Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] [CRCTB] | |
| dc.contributor.author | GRUSON, Didier | |
| dc.contributor.author | LOUIS, Guillaume | |
| hal.structure.identifier | Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] [CRCTB] | |
| dc.contributor.author | BOYER, Alexandre | |
| dc.date.accessioned | 2024-03-13T12:12:00Z | |
| dc.date.available | 2024-03-13T12:12:00Z | |
| dc.date.issued | 2024-02-13 | |
| dc.identifier.issn | 2110-5820 (Print) 2110-5820 (Electronic) 2110-5820 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/188781 | |
| dc.description.abstractEn | BACKGROUND: Acute kidney injury (AKI) in intensive care unit (ICU) patients with severe COVID-19 is common (> 50%). A specific inflammatory process has been suggested in the pathogenesis of AKI, which could be improved by dexamethasone (DXM). In a small monocenter study (n = 100 patients), we reported a potential protective effect of DXM on the risk of AKI. This study aimed to investigate the preventive impact of DXM on AKI in a multicenter study of patients with severe COVID-19. METHODS: We conducted a multicenter study in three French ICUs from March 2020 to August 2021. All patients admitted to ICU for severe COVID-19 were included. Individuals with preexistent AKI or DXM administration before admission to ICU were excluded. While never used during the first wave, DXM was used subsequently at ICU entry, providing two treatment groups. Multivariate Cause-specific Cox models taking into account changes in ICU practices over time, were utilized to determine the association between DXM and occurrence of AKI. RESULTS: Seven hundred and ninety-eight patients were included. Mean age was 62.6 +/- 12.1 years, 402/798 (50%) patients had hypertension, and 46/798 (6%) had previous chronic kidney disease. Median SOFA was 4 [3-6] and 420/798 (53%) required invasive mechanical ventilation. ICU mortality was 208/798 (26%). AKI was present in 598/798 (75%) patients: 266/598 (38%), 163/598 (27%), and 210/598 (35%) had, respectively, AKI KDIGO 1, 2, 3, and 61/598 (10%) patients required renal replacement therapy. Patients receiving DXM had a significantly decreased hazard of AKI occurrence compared to patients without DXM (HR 0.67; 95CI 0.55-0.81). These results were consistent in analyses that (1) excluded patients with DXM administration to AKI onset delay of less than 12 h, (2) incorporating the different 'waves' of the COVID-19 pandemic. CONCLUSIONS: DXM was associated with a decrease in the risk of AKI in severe COVID-19 patients admitted to ICU. This supports the hypothesis that the inflammatory injury of AKI may be preventable. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject.en | Acute kidney injury | |
| dc.subject.en | Intensive care unit | |
| dc.subject.en | COVID-19 | |
| dc.subject.en | Dexamethasone | |
| dc.title.en | Impact of dexamethasone in severe COVID-19-induced acute kidney injury: a multicenter cohort study | |
| dc.title.alternative | Ann Intensive Care | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1186/s13613-024-01258-6 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 38349530 | en_US |
| bordeaux.journal | Annals of Intensive Care | en_US |
| bordeaux.page | 26 | en_US |
| bordeaux.volume | 14 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 1 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | LEHA_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-04502801 | |
| hal.version | 1 | |
| hal.date.transferred | 2024-03-13T12:12:02Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Annals%20of%20Intensive%20Care&rft.date=2024-02-13&rft.volume=14&rft.issue=1&rft.spage=26&rft.epage=26&rft.eissn=2110-5820%20(Print)%202110-5820%20(Electronic)%202110-5820%20(Linking)&rft.issn=2110-5820%20(Print)%202110-5820%20(Electronic)%202110-5820%20(Linking)&rft.au=RUBIN,%20Sebastien&ORIEUX,%20Arthur&PREZELIN-REYDIT,%20Mathilde&GARRIC,%20Antoine&PICARD,%20Yoann&rft.genre=article |
